Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens

Takakuwa,Osamu; Oguri,Tetsuya; Maeno,Ken; Ozasa,Hiroaki; Iwashima,Yasuhito; Miyazaki,Mikinori; Kunii,Hideharu; Takano,Yuko; Mori,Toshiyuki; Sato,Shigeki; Ueda,Ryuzo

doi:10.3892/ol_00000027

Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens

Authors:
- Osamu Takakuwa
- Tetsuya Oguri
- Ken Maeno
- Hiroaki Ozasa
- Yasuhito Iwashima
- Mikinori Miyazaki
- Hideharu Kunii
- Yuko Takano
- Toshiyuki Mori
- Shigeki Sato
- Ryuzo Ueda
View Affiliations

Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000027
Pages: 147-150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The efficacy and safety of S-1 monotherapy for patients with advanced or recurrent non-small cell lung cancer (NSCLC) after the failure of two or more prior chemotherapy regimens were investigated. Records of 36 patients with advanced or recurrent NSCLC who received S-1 monotherapy between January 2005 and December 2008, following the failure of previous chemotherapy, were reviewed retrospectively at two institutions. S-1 was given orally twice daily on days 1-28 every six weeks; the dose was based on body surface area. The median number of prior chemotherapy regimens was three (range 2-5), and that of courses given per patient was two (range 1-10). No patient achieved complete response, 4 patients (11.1%) achieved partial response, 10 patients (27%) had stable disease and 18 patients (50%) had progressive disease. The median progression-free survival was 3 months and the median overall survival was 15.2 months. No grade 4 hematological toxicity was noted. Grade ≥3 non-hematological toxicities were observed in 5 patients (13.9%). No deaths related to S-1 monotherapy occurred. S-1 monotherapy exhibits activity with acceptable toxicity as third-line or subsequent chemotherapy for advanced NSCLC.

View Figures

View References

1	Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000.
2	Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 18:2354–2362. 2000.
3	Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
6	Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 78:748–755. 1987.PubMed/NCBI
7	Oguri T, Achiwa H, Bessho Y, et al: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 49:345–351. 2005. View Article : Google Scholar : PubMed/NCBI
8	Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its anti-tumor activity in rats. Cancer Res. 53:4004–4009. 1993.PubMed/NCBI
9	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–211. 2008. View Article : Google Scholar : PubMed/NCBI
10	Saeki T, Takashima S, Sano M, et al: A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer. 11:194–202. 2004. View Article : Google Scholar : PubMed/NCBI
11	Goto A, Yamada Y, Yasui H, et al: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 17:968–973. 2006. View Article : Google Scholar : PubMed/NCBI
12	Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Phamacol. 61:615–621. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer. Br J Cancer. 85:939–943. 2001. View Article : Google Scholar : PubMed/NCBI
14	Furuse K, Kawahara M, Hasegawa K, et al: Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small cell lung cancer. Int J Clin Oncol. 6:236–241. 2001. View Article : Google Scholar : PubMed/NCBI
15	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
16	Massarelli E, Andre F, Liu DD, et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer. 39:55–61. 2003. View Article : Google Scholar : PubMed/NCBI
17	Igawa S, Takahashi T, Nakamura Y, et al: Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens. Anticancer Res. 28:3855–3858. 2008.PubMed/NCBI
18	Kurakawa E, Kasuga I, Ishizuka S, et al: Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Jpn J Clin Oncol. 31:284–286. 2001. View Article : Google Scholar : PubMed/NCBI
19	DeMario MD and Ratain MJ: Oral chemotherapy: rational and future directions. J Clin Oncol. 16:2557–2567. 1998.PubMed/NCBI